COMP <GO>
ASND vs BBIO // DIVIDEND YIELD & FCF PAYOUT SAFETY
Ascendis Pharma A/S Ordinary Share (NASDAQ) VS. BridgeBio Pharma Inc. (NASDAQ) • 15-METRIC TALLY: ASND 8
— BBIO 3
■ METRIC PARITY
LAST: $248.98 (-0.91%) • MKT CAP: $16.55B
dividend-safety
0.00%
LAST: $75.00 (+0.06%) • MKT CAP: $14.60B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ASND VS. BBIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ASND | BBIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 95.80% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | -35.00% | +44.90 | ASND | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | -3.23% | +5.44 | ASND | /fcf-yield <GO> |
| Operating Margin | 13.90% | -60.00% | +73.90 | ASND | /operating-margins <GO> |
| Net Profit Margin | 10.90% | -60.00% | +70.90 | ASND | /net-margins <GO> |
| Revenue Growth (YoY) | 12.10% | 126.30% | -114.20 | BBIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 0.45 | +3.29 | ASND | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 4/9 | +4.00 | ASND | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 63.3 | 63.9 | -0.60 | BBIO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.00 | -0.02 | BBIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.6x | 33.0x | -5.40 | ASND | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.55B | $14.60B | $1.95B | ASND | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ASND REV | BBIO REV | ASND GROSS % | BBIO GROSS % | ASND FCF | BBIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $502.1M | — | 95.8% | — | -$447.0M |
| FY 2024 | — | $221.9M | — | 98.3% | — | -$521.7M |
| FY 2023 | — | $9.3M | — | — | — | -$528.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ASND // BETA 0.98
BBIO // BETA 1.00